Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 3/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | EIF4E | P06730 | 6/20 | 0.40 |
| ▸ | KDM4A | O75164 | 1/20 | 0.39 |
| ▸ | KDM4B | O94953 | 1/20 | 0.39 |
| ▸ | KDM5C | P41229 | 1/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.39 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.37 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.37 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6517121 | 0.82 | FAAH (0.43) | CHEK2ABL1PARP1KDM4AKDM4B | |
| SCHEMBL6513038 | 0.80 | ECE1 (0.45) | P2RX7CHEK2KMOKDM4E | |
| SCHEMBL15943367 | 0.77 | AHR (0.48) | ABL1KMOKDM4ENPC1RAB9A | |
| SCHEMBL6522482 | 0.77 | RORC (0.40) | P2RX7CHEK2PARP1KAT6ARORC | |
| SCHEMBL6512405 | 0.76 | ESR2 (0.46) | CHEK2KDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL1772805 | 0.74 | METAP2 (0.38) | CHEK2PARP1KDM4AKDM4BKDM5C | |
| SCHEMBL7855714 | 0.74 | KAT6A (0.54) | CHEK2ABL1KDM4AKDM4BKDM5C | |
| SCHEMBL4524262 | 0.73 | KMO (0.47) | CHEK2ABL1KMOKDM4E | |
| SCHEMBL10965370 | 0.73 | MKNK2 (0.48) | P2RX7KMO | |
| SCHEMBL15384396 | 0.73 | KMO (0.50) | P2RX7KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949536-B2 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | PFIZER, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20040157824-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | PFIZER INC. | 2004-08-12 | — | — | US | disclosed |
| EP-1086097-B1 | SULFONYLBENZENE COMPOUNDS AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | PFIZER (US) | 2004-05-19 | — | — | EP | disclosed |
| US-6727238-B2 | CYCLOOXYGENASE INHIBITORS | PFIZER INC. | 2004-04-27 | — | — | US | disclosed |
| US-20030225064-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | ANDO KAZUO (JP) | 2003-12-04 | — | — | US | disclosed |
| US-6608095-B2 | Sulfonylbenzene and sulfonamidobenzene compounds which inhibit COX-2; treatment of a medical condition in which prostaglandins are implicated as pathogens | PFIZER INC. | 2003-08-19 | — | — | US | disclosed |
| US-20020045654-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | ANDO KAZUO (JP) | 2002-04-18 | — | — | US | disclosed |
| US-6294558-B1 | ANTIINFLAMMATORY AGENTS AND PROSTAGLANTINS | PFIZER INC. | 2001-09-25 | — | — | US | disclosed |
| EP-1086097-A1 | SULFONYLBENZENE COMPOUNDS AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | PFIZER INC. (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999064415-A1 | SULFONYLBENZENE COMPOUNDS AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157824-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | CNR1, PTGS1, PTGER1 | P2RX7 106/4885CHEK2 4844/4885ABL1 2966/4885 |
| US-20020045654-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | CNR1, PTGER1, PTGS1 | P2RX7 94/4885CHEK2 4842/4885ABL1 2747/4885 |
| US-20030225064-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | CNR1, PTGS1, PTGER1 | P2RX7 106/4885CHEK2 4844/4885ABL1 2966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.